Docetaxel and GEM 231 in Treating Patients With Recurrent or Refractory Solid Tumors
Status:
Completed
Trial end date:
2000-06-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die. Gene therapy such as GEM 231 may inhibit the growth of cancer cells
and make the tumor more sensitive to chemotherapy.
PURPOSE: Phase I trial to study the effectiveness of combining docetaxel and GEM 231 in
treating patients who have recurrent or refractory solid tumors.